AbbVie Stock Price, News & Analysis (NYSE:ABBV)

AbbVie trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABBV."

AbbVie announced a -- dividend on Monday, September 9th. Investors of record on Tuesday, October 15th will be paid a dividend of $1.07 per share on Friday, November 15th. This represents a dividend yield of 6.4%. The ex-dividend date is Friday, October 11th. View AbbVie's Dividend History.

AbbVie declared that its board has approved a stock repurchase plan on Thursday, December 13th 2018, which authorizes the company to buyback $5,000,000,000.00 in shares, according to EventVestor. This buyback authorization authorizes the company to purchase up to 3.8% of its shares through open market purchases. Shares buyback plans are often an indication that the company's management believes its shares are undervalued.

AbbVie Inc (NYSE:ABBV) posted its quarterly earnings data on Friday, July, 26th. The company reported $2.26 EPS for the quarter, beating the consensus estimate of $2.21 by $0.05. The company earned $8.26 billion during the quarter, compared to analysts' expectations of $8.09 billion. AbbVie had a negative return on equity of 182.70% and a net margin of 12.62%. The company's revenue was down .3% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.00 earnings per share. View AbbVie's Earnings History.

AbbVie is scheduled to release their next quarterly earnings announcement on Friday, November 1st 2019. View Earnings Estimates for AbbVie.

AbbVie will be holding an earnings conference call on Friday, November 1st at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

AbbVie updated its FY19 earnings guidance on Friday, July, 26th. The company provided earnings per share (EPS) guidance of $8.82-8.92 for the period, compared to the Thomson Reuters consensus estimate of $8.78.

15 Wall Street analysts have issued 12-month price objectives for AbbVie's stock. Their forecasts range from $66.61 to $135.00. On average, they expect AbbVie's share price to reach $89.20 in the next year. This suggests a possible upside of 16.7% from the stock's current price. View Analyst Price Targets for AbbVie.

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AbbVie in the last year. There are currently 1 sell rating, 6 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for AbbVie.

Media coverage about ABBV stock has been trending somewhat negative this week, according to InfoTrie. The research group identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. AbbVie earned a daily sentiment score of -1.5 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for AbbVie.

Some companies that are related to AbbVie include Johnson & Johnson (JNJ), Roche Holdings AG Basel (RHHBY), Merck & Co., Inc. (MRK), Pfizer (PFE), Novartis (NVS), Abbott Laboratories (ABT), Novo Nordisk A/S (NVO), AstraZeneca (AZN), Sanofi (SNY), GlaxoSmithKline (GSK), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Commonwealth Bank of Australia (CSLLY), Celgene (CELG) and Bayer (BAYRY).

Based on aggregate information from My MarketBeat watchlists, some companies that other AbbVie investors own include Intact Financial (IFC), Constellation Software (CSU), AutoCanada (ACQ), Alimentation Couche-Tard (ATD.B), Vermilion Energy (VET), Wheaton Precious Metals (WPM), Rogers Communications (RCI), Open Text (OTEX), Valeant Pharmaceuticals Intl (VRX) and Toronto-Dominion Bank (TD).

AbbVie's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Robeco Institutional Asset Management B.V. (0.20%), Envestnet Asset Management Inc. (0.09%), PGGM Investments (0.08%), Hamlin Capital Management LLC (0.07%), Artemis Investment Management LLP (0.06%) and Miller Howard Investments Inc. NY (0.05%). Company insiders that own AbbVie stock include Azita Saleki-Gerhardt, Brian L Durkin, Carlos Alban, Edward J Rapp, Glenn F Tilton, Henry O Gosebruch, Istar Inc, Jeffrey Ryan Stewart, Laura J Schumacher, Michael Severino, Nicholas Donoghoe, Richard A Gonzalez, Robert A Michael, Roxanne S Austin, Timothy J Richmond and William J Chase. View Institutional Ownership Trends for AbbVie.

ABBV stock was sold by a variety of institutional investors in the last quarter, including Artemis Investment Management LLP, Park National Corp OH, Bowling Portfolio Management LLC, Security National Bank, Gateway Investment Advisers LLC, Decatur Capital Management Inc., Nisa Investment Advisors LLC and Pioneer Trust Bank N A OR. Company insiders that have sold AbbVie company stock in the last year include Azita Saleki-Gerhardt, Brian L Durkin, Henry O Gosebruch, Laura J Schumacher, Richard A Gonzalez, Timothy J Richmond and William J Chase. View Insider Buying and Selling for AbbVie.

ABBV stock was acquired by a variety of institutional investors in the last quarter, including PGGM Investments, Miller Howard Investments Inc. NY, Robeco Institutional Asset Management B.V., Commerzbank Aktiengesellschaft FI, TIAA FSB, Rhenman & Partners Asset Management AB, Hamlin Capital Management LLC and Envestnet Asset Management Inc.. Company insiders that have bought AbbVie stock in the last two years include Edward J Rapp, Glenn F Tilton, Henry O Gosebruch, Istar Inc, Jeffrey Ryan Stewart, Laura J Schumacher, Nicholas Donoghoe, Roxanne S Austin and William J Chase. View Insider Buying and Selling for AbbVie.

Shares of ABBV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ABBV stock can currently be purchased for approximately $76.46.

AbbVie has a market capitalization of $113.04 billion and generates $32.75 billion in revenue each year. The company earns $5.69 billion in net income (profit) each year or $7.91 on an earnings per share basis. AbbVie employs 30,000 workers across the globe.View Additional Information About AbbVie.

The official website for AbbVie is http://www.abbvie.com/.

AbbVie's mailing address is 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. The company can be reached via phone at 847-932-7900.